Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine ± hydromorphone serratus anterior plane block after thoracoscopic lobectomy
ChiCTR2100053893Phase 4Not yet recruiting
- Sponsor
- Shaoxing Shangyu People's Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydromorphone and ropivacaine in bronchial carcinoma (3 arms), sponsored by Shaoxing Shangyu People's Hospital. Primary endpoints: Visual analogue scale score, Interleukin-10 (IL-10) and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
hydromorphoneropivacaine
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2100053893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053893.